Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia

Jonas Paludo, Jithma P. Abeykoon, Amanda Shreders, Stephen M. Ansell, Shaji Kumar, Sikander Ailawadhi, Rebecca L. King, Amber B. Koehler, Craig B. Reeder, Francis K. Buadi, Angela Dispenzieri, Martha Q. Lacy, David Dingli, Thomas E. Witzig, Ronald S. Go, Wilson I. Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Nelson Leung, Thomas M. HabermannSuzanne Hayman, Yi Lin, Robert A. Kyle, S. Vincent Rajkumar, Morie A. Gertz, Prashant Kapoor

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia'. Together they form a unique fingerprint.

Medicine & Life Sciences